JNJ-26481585 Size:2mg solid type I) mediated lipid transfer

type I) mediated lipid transfer

InChiKey: GXCGXOBFROXMLV-UHFFFAOYSA-N

39(6):603-5

ADX47273 increased extracellular signal-regulated kinase and cAMP-responsive element-binding protein phosphorylation in hippocampus and prefrontal cortex

Suplatast tosilate (100 mg/kg/100 μL) significantly reduces the number of total cells and eosinophils in BALF (around -40%) and almost completely inhibits the development of antigen-induced BHR

JNJ-26481585 Size:2mg solid type I) mediated lipid transferQuisinostat (USAN; development code JNJ 26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs. Product information CAS Number: 875320 29 9 Molecular Weight: 394. 47 Formula: C21H26N6O2 Synonym: Quisinostat Related CAS Number: 1083078 98 1 (Quisinostat hydrochloride) 875320 31 3 (Quisinostat